5th Apr 2006 14:00
Skyepharma PLC05 April 2006 For Immediate Release 5 April 2006 SkyePharma PLC SkyePharma's Chief Executive Appointed to Board LONDON, UK, 5 April 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE)announces that at a Board meeting yesterday its Chief Executive, Frank Condella,was appointed a Director of the Company. It was announced in February that MrCondella, previously President of the European operations of IVAX prior to itsacquisition by Teva in 2005, would become Chief Executive of SkyePharma and hetook up this appointment on1 March. Frank Condella said: "I am pleased to be joining the Board. I have now completedmy initial review of SkyePharma's operations and I have been impressed by theCompany's employees, products and technologies. I look forward to working withmy fellow directors to restructure our business and deliver sustainableprofitability for the benefit of all shareholders." Dr Jerry Karabelas, SkyePharma's Non-executive Chairman, said: "I am delightedto welcome Frank to the Board, where his long experience as a seniorinternational manager in the pharmaceutical industry will provide us withvaluable input. We are working together to implement the strategy we set inplace earlier this year and I hope soon to be able to report to shareholders onprogress." For further information please contact: SkyePharma PLC Frank Condella, Chief Executive +44 207 491 1777 Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich Notes for editors About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now twelve approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Certain statements in this news release are forward-looking statements and aremade in reliance on the safe harbour provisions of the U.S. Private SecuritiesLitigation Act of 1995. Although SkyePharma believes that the expectationsreflected in these forward-looking statements are reasonable, it can give noassurance that these expectations will materialize. Because the expectations aresubject to risks and uncertainties, actual results may vary significantly fromthose expressed or implied by the forward-looking statements based upon a numberof factors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. Factors that could cause differences between actual results andthose implied by the forward-looking statements contained in this news releaseinclude, without limitation, risks related to the development of new products,risks related to obtaining and maintaining regulatory approval for existing, newor expanded indications of existing and new products, risks related toSkyePharma's ability to manufacture products on a large scale or at all, risksrelated to SkyePharma's and its marketing partners' ability to market productson a large scale to maintain or expand market share in the face of changes incustomer requirements, competition and technological change, risks related toregulatory compliance, the risk of product liability claims, risks related tothe ownership and use of intellectual property, and risks related toSkyePharma's ability to manage growth. SkyePharma undertakes no obligation torevise or update any such forward-looking statement to reflect events orcircumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L